October 2020, Vol 1, No 2

Many oncologists and patients believe that precision medicine holds the promise of bypassing the traditional one-size-fits-all approach in oncology, its real-world use is not yet meeting up to its high hopes. On August 24, 2020, the European Society for Medical Oncology (ESMO) released the first recommendations from a scientific society about the use of multigene next-generation sequencing (NGS).
Read More

The multidrug combination of toripalimab, a new PD-1 inhibitor, plus lenvatinib (Lenvima), a multikinase inhibitor, and the chemotherapy drugs gemcitabine and oxaliplatin demonstrated promising efficacy in patients with advanced, unresectable intrahepatic cholangiocarcinoma (CCA), according to results of a phase 2 clinical trial presented at the 2020 virtual meeting of the European Society for Medical Oncology.
Read More

Cholangiocarcinoma (CCA) is a cancer arising from the intra- or extra-hepatic bile ducts, mainly characterized by its late diagnosis and fatal outcome. Painless obstructive jaundice is a common presenting symptom and managing the malignant biliary obstruction to ensure adequate drainage is necessary to effectively treat both cholangiocarcinoma and a subset of pancreatic cancer patients (those with disease in the head of the pancreas).
Read More

Cholangiocarcinoma (CCA) is a rare type of cancer that arises from the intrahepatic or extrahepatic biliary ductal epithelium, accounting for approximately 10% to 15% of all primary hepatic malignancies. CCA is classified as intrahepatic or extrahepatic CCA. In the United States, the incidence of CCA has been rising consistently since 1973.
Read More

Page 2 of 2


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: